百奥泰:2025一季报净利润-0.93亿 同比增长21.85%

Financial Data and Indicators - The basic earnings per share for Q1 2025 is -0.2300 yuan, showing a 20.69% improvement compared to -0.2900 yuan in Q1 2024 [1] - The net asset per share decreased by 43.94% to 1.48 yuan from 2.64 yuan in the previous year [1] - The operating revenue for Q1 2025 increased by 27.78% to 2.07 billion yuan compared to 1.62 billion yuan in Q1 2024 [1] - The net profit for Q1 2025 is -0.93 billion yuan, an improvement of 21.85% from -1.19 billion yuan in Q1 2024 [1] - The return on equity for Q1 2025 is -14.11%, a decline of 36.72% from -10.32% in Q1 2024 [1] Shareholder Information - The top ten unrestricted shareholders hold a total of 31,408.05 million shares, accounting for 75.84% of the circulating shares, with a decrease of 384.87 million shares compared to the previous period [2] - Guangzhou Qixi Group Co., Ltd. holds 15,999.03 million shares, representing 38.64% of the total share capital, with no change [3] - Therabio International Limited holds 4,717.77 million shares, accounting for 11.39% of the total share capital, with no change [3] - New Yu City Qiheng Management Consulting Partnership (Limited Partnership) decreased its holdings by 384.87 million shares to 1,614.31 million shares, representing 3.90% of the total share capital [3] Dividend Distribution - The company will not distribute dividends or transfer shares this time [4]